{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:32:23Z","timestamp":1781069543309,"version":"3.54.1"},"reference-count":15,"publisher":"Pharmaceutical Society of Japan","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,11,28]]},"DOI":"10.1248\/bpb.b25-00574","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T22:08:28Z","timestamp":1764281308000},"page":"1830-1833","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Study of Histone Deacetylase Inhibitors for Radiation Protection Using Survival Outcomes in a Mouse Model"],"prefix":"10.1248","volume":"48","author":[{"given":"Yukiro","family":"Kurokawa","sequence":"first","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"},{"name":"Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4\u20132 Bunkyo-cho, Matsuyama, Ehime 790\u20138578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4\u20132 Bunkyo-cho, Matsuyama, Ehime 790\u20138578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4\u20132 Bunkyo-cho, Matsuyama, Ehime 790\u20138578, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Maci\u00e0 I.Garau M, Lucas Calduch A, L\u00f3pez EC. Radiobiology of the acute radiation syndrome. <i>Rep. Pract. Oncol. Radiother.<\/i>, <b>16<\/b>, 123\u2013130 (2011).","DOI":"10.1016\/j.rpor.2011.06.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability. <i>Genes<\/i>, <b>11<\/b>, 556 (2020).","DOI":"10.3390\/genes11050556"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ling R, Wang J, Fang Y, Yu Y, Su Y, Sun W, Li X, Tang X. HDAC\u2014an important target for improving tumor radiotherapy resistance. <i>Front. Oncol.<\/i>, <b>13<\/b>, 1193637 (2023).","DOI":"10.3389\/fonc.2023.1193637"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. <i>Biologics<\/i>, <b>7<\/b>, 47\u201360 (2013).","DOI":"10.2147\/BTT.S29965"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Whittle JR, Desai J. Histone deacetylase inhibitors in cancer: what have we learned? <i>Cancer<\/i>, <b>121<\/b>, 1164\u20131167 (2015).","DOI":"10.1002\/cncr.29177"},{"key":"6","unstructured":"6) Roos WP, Krumm A, Temme A, Kerr M, Kiltie AE. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. <i>Cancer Lett.<\/i>, <b>368<\/b>, 207\u2013216 (2016)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Brown SL, Kolozsvary A, Liu J, Ryu S, Kim JH. Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. <i>Radiat. Res.<\/i>, <b>169<\/b>, 474\u2013478 (2008).","DOI":"10.1667\/RR1245.1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) G\u00f6ttlicher M, Minucci S, Zhu P, Kr\u00e4mer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. <i>EMBO J.<\/i>, <b>20<\/b>, 6969\u20136978 (2001).","DOI":"10.1093\/emboj\/20.24.6969"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Liu G, Lim D, Cai Z, Ding W, Tian Z, Dong C, Zhang F, Guo G, Wang X, Zhou P, Feng Z. The valproate mediates radio-bidirectional regulation through RFWD3-dependent ubiquitination on Rad51. <i>Front. Oncol.<\/i>, <b>11<\/b>, 646256 (2021).","DOI":"10.3389\/fonc.2021.646256"},{"key":"10","unstructured":"10) Tsai YT, Lin CJ, Tsai Y, Hsu YF, Sheu JR, Ou G, Hsu MJ. Valproic acid suppresses lipopolysaccharide-induced cyclooxygenase-2 expression <i>via<\/i> MKP-1 in murine brain microvascular endothelial cells. <i>Neurochem. Int.<\/i>, <b>59<\/b>, 1060\u20131067 (2011)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Chen X, Wang H, Zhou M, Li X, Fang Z, Gao H, Li Y, Hu W. Valproic acid attenuates traumatic brain injury-induced inflammation <i>in vivo<\/i>: involvement of autophagy and the Nrf2\/ARE signaling pathway. <i>Front. Mol. Neurosci.<\/i>, <b>11<\/b>, 117 (2018).","DOI":"10.3389\/fnmol.2018.00117"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Luo HM, Hu S, Bai HY, Wang HB, Du MH, Lin ZL, Ma L, Wang H, Lv Y, Sheng ZY. Valproic acid treatment attenuates caspase-3 activation and improves survival after lethal burn injury in a rodent model. <i>J. Burn Care Res.<\/i>, <b>35<\/b>, e93\u2013e98 (2014).","DOI":"10.1097\/BCR.0b013e31828a8d32"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. <i>World J. Gastroenterol.<\/i>, <b>17<\/b>, 1519\u20131528 (2011).","DOI":"10.3748\/wjg.v17.i12.1519"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Li W, Sun Z. Mechanism of action for HDAC inhibitors\u2014insights from omics approaches. <i>Int. J. Mol. Sci.<\/i>, <b>20<\/b>, 1616 (2019).","DOI":"10.3390\/ijms20071616"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. <i>BioMed Res. Int.<\/i>, <b>2016<\/b>, 8797206 (2016).","DOI":"10.1155\/2016\/8797206"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00574\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T03:24:13Z","timestamp":1764386653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/11\/48_b25-00574\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00574","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"article-number":"b25-00574"}}